Please assess the completion status of the following clinical trial:

Trial Title: Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 18 to 65 years of age~2. Diagnosis of RA, according to ACR criteria (1987), of at least 6 months duration~3. At randomization, tender joint count ≥ 6 and swollen joint count ≥ 6~4. Evidence of at least moderate disease activity~5. Patients receiving oral or parenteral MTX with a dose of 15 to 25 mg per week when given alone or 10 to 25 mg per week in combination with additional non-biologic DMARD(s) for at least 6 months and on stable dose for at least 3 months~6. Patients must be on a stable dose of folic acid or equivalent (≥5 mg per week)~7. Chest X-ray not suggestive of any lung infections including pulmonary tuberculosis (TB)~8. Contraception required per protocol~Exclusion Criteria:~1. Prior therapy with~   * Rituximab, abatacept, tocilizumab, anakinra or an agent/antibody targeting CD20, CD19 or B cells~  * Tumor necrosis factor (TNF) alfa antagonists or other biologic DMARDs~   Other prior or concurrent therapies may also be excluded~2. Any clinically relevant abnormality detected on screening history, physical examination, clinical laboratory, chest X-ray, or electrocardiogram (ECG), other than values consistent with RA~3. Evidence of active, suspected or inadequately treated TB~4. Positive serological test for hepatitis C virus antibodies, hepatitis B surface antigen, hepatitis B core antibody, or human immunodeficiency virus~5. History of cardiovascular disease, history of stroke, or uncontrolled hypertension~6. History of lymphoproliferative disease or organ allograft~7. History of cancer (except for in situ cancer, excised, or limited stage, curatively treated cancer with no sign of disease for \>5 years)~8. History of allergy (medication history) to any of the compounds used in the study~9. Pregnant or lactating women or women planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DRL_RI (Type: EXPERIMENTAL): None
- Rituxan (Type: ACTIVE_COMPARATOR): None
- MabThera (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).